These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28738426)

  • 1. Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.
    Hiramatsu T; Ozeki A; Ishikawa H; Furuta S
    Drug Res (Stuttg); 2017 Nov; 67(11):640-646. PubMed ID: 28738426
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
    Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
    Zavattaro M; Caputo M; Samà MT; Mele C; Chasseur L; Marzullo P; Pagano L; Mauri MG; Ponziani MC; Aimaretti G; Prodam F
    Endocrine; 2015 Dec; 50(3):620-6. PubMed ID: 25572181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.
    Hiramatsu T; Ozeki A; Asai K; Saka M; Hobo A; Furuta S
    Ther Apher Dial; 2015 Dec; 19(6):598-605. PubMed ID: 26556397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of liraglutide on renal function: A randomized clinical trial.
    von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.
    Hiramatsu T; Asano Y; Mabuchi M; Imai K; Iguchi D; Furuta S
    Eur J Clin Invest; 2018 Oct; 48(10):e13007. PubMed ID: 30054920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
    Yoon SA; Han BG; Kim SG; Han SY; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang YH; Shin SH; Cha DR
    Diabetes Obes Metab; 2017 Apr; 19(4):590-598. PubMed ID: 28019072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
    Rondinelli M; Rossi A; Gandolfi A; Saponaro F; Bucciarelli L; Adda G; Molinari C; Montefusco L; Specchia C; Chiara Rossi M; Scardapane M; Arosio M; Genovese S
    Clin Ther; 2017 Jan; 39(1):159-169. PubMed ID: 27939305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annual deterioration of renal function in hypertensive patients with and without diabetes.
    Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
    Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
    von Scholten BJ; Hansen TW; Goetze JP; Persson F; Rossing P
    J Diabetes Complications; 2015 Jul; 29(5):670-4. PubMed ID: 25935863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.
    Osonoi T; Gouda M; Kubo M; Arakawa K; Hashimoto T; Abe M
    Diabetes Technol Ther; 2018 Oct; 20(10):681-688. PubMed ID: 30096243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
    Zobel EH; von Scholten BJ; Lindhardt M; Persson F; Hansen TW; Rossing P
    J Diabetes Complications; 2017 Jan; 31(1):162-168. PubMed ID: 27769801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
    Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.
    Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R
    J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
    Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.
    Chang KC; Shao SC; Kuo S; Yang CY; Chen HY; Chan YY; Ou HT
    Cardiovasc Diabetol; 2020 Oct; 19(1):172. PubMed ID: 33036617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB;
    N Engl J Med; 2017 Aug; 377(9):839-848. PubMed ID: 28854085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.